Samsung Bioepis Initiates Phase 3 Clinical Trial for Proposed Pembrolizumab Biosimilar : vimarsana.com

The trial will compared the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 and pembrolizumab for metastatic non-squamous non-small cell lung cancer.

Related Keywords

Ilsun Hong , Gallaghera Samsung Bioepis , Samsung Bioepis , Keytruda Biosimilar , Keytruda Pembrolizumab , Samsung Bioepis Co Ltd , Product Evaluation Team Leader Of Samsung Bioepis , Product Evaluation Team Leader , European Union Sourced , United States Sourced , Immunogenicity Between , Bioepis Initiates Phase , Proposed Biosimilar , Proposed Keytruda ,